AU2001239791A1 - Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production - Google Patents

Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production

Info

Publication number
AU2001239791A1
AU2001239791A1 AU2001239791A AU3979101A AU2001239791A1 AU 2001239791 A1 AU2001239791 A1 AU 2001239791A1 AU 2001239791 A AU2001239791 A AU 2001239791A AU 3979101 A AU3979101 A AU 3979101A AU 2001239791 A1 AU2001239791 A1 AU 2001239791A1
Authority
AU
Australia
Prior art keywords
succinoylamino
carbocycles
heterocycles
inhibitors
protein production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239791A
Inventor
Wei Deng
Hong Liu
Thomas P. MADUSKUIE JR.
Richard E. Olson
Andrew J. Tebben
Lorin Andrew Thompson
Nenghui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2001239791A1 publication Critical patent/AU2001239791A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
AU2001239791A 2000-02-17 2001-02-16 Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production Abandoned AU2001239791A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18318600P 2000-02-17 2000-02-17
US60183186 2000-02-17
PCT/US2001/005236 WO2001060826A2 (en) 2000-02-17 2001-02-16 SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION

Publications (1)

Publication Number Publication Date
AU2001239791A1 true AU2001239791A1 (en) 2001-08-27

Family

ID=22671796

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239791A Abandoned AU2001239791A1 (en) 2000-02-17 2001-02-16 Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production

Country Status (6)

Country Link
US (1) US6525044B2 (en)
EP (1) EP1261610A2 (en)
JP (1) JP2003523345A (en)
AU (1) AU2001239791A1 (en)
CA (1) CA2395862A1 (en)
WO (1) WO2001060826A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9917082A (en) 1998-12-24 2001-11-06 Du Pont Pharm Co Compounds that inhibit the production of "beta" proteins, a method of treating neurological disorders associated with the production of "beta" -amyloid, pharmaceutical composition and, method of inhibiting y-secretase activity
AU2001239791A1 (en) 2000-02-17 2001-08-27 Du Pont Pharmaceuticals Company Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
BR0106717A (en) * 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compounds, pharmaceutical composition and uses of innovative lactam compounds
AU2002367147A1 (en) * 2001-12-27 2003-07-15 Daiichi Pharmaceutical Co., Ltd. Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
US20050266099A1 (en) * 2002-04-25 2005-12-01 Alon Shalev Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
JP2006515999A (en) * 2002-11-14 2006-06-15 ブレインズゲート リミティド Surgical tools and techniques for stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
CN101395143A (en) * 2005-12-29 2009-03-25 安姆弗拉玛法国股份公司 Aza heterocyclics for the treatment of malaria or aids
AU2006331355B2 (en) * 2005-12-29 2011-09-29 Immupharma France Sa Compositions and methods for the inhibition of phospholipase A2
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
JP2010518064A (en) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Piperazine derivatives for the treatment of AD and related conditions
CN101284828B (en) * 2007-04-12 2011-04-27 中国科学院上海药物研究所 Cycloheptapyridine compounds, preparation method thereof, use and pharmaceutical compositions containing the compounds
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2011007756A1 (en) 2009-07-13 2011-01-20 武田薬品工業株式会社 Heterocyclic compound and use thereof
WO2012029991A1 (en) 2010-09-02 2012-03-08 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
TWI530489B (en) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JP2015534553A (en) * 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
TWI614238B (en) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof
EP2897947B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
JP2015529253A (en) * 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as Notch inhibitors
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN104854097A (en) * 2012-09-21 2015-08-19 百时美施贵宝公司 N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
CN104968648A (en) * 2012-09-21 2015-10-07 百时美施贵宝公司 Prodrugs of 1, 4-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
WO2014165718A1 (en) 2013-04-04 2014-10-09 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2630440B1 (en) * 1988-04-25 1991-09-20 Jouveinal Sa BENZODIAZEPINES, THEIR PREPARATION PROCESS AND INTERMEDIATES AND THEIR THERAPEUTIC APPLICATIONS
EP0727215A3 (en) 1989-08-04 1996-11-06 Merck Sharp & Dohme Central cholecystokinin antagonists for treatment of psychiatric disorders
CA2026856A1 (en) 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
IE904560A1 (en) 1989-12-18 1991-06-19 Merck & Co Inc New benzodiazepine analogs
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
DK0652871T3 (en) 1992-07-29 2001-12-03 Merck Sharp & Dohme Absorbent article with fastening system that provides dynamic fit of elasticated waistband
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
CN1041921C (en) 1992-12-21 1999-02-03 史密丝克莱恩比彻姆公司 Bicyclic fibrinogen antagonists
MX9308016A (en) 1992-12-22 1994-08-31 Lilly Co Eli HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM.
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
EP0702671A4 (en) 1993-06-09 1996-06-19 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5426185A (en) 1993-11-22 1995-06-20 Merck & Co., Inc. Antiarrhythmic benzodiazepines
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0804425A2 (en) 1994-07-29 1997-11-05 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996017833A1 (en) 1994-12-09 1996-06-13 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5639746A (en) 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
JPH10510537A (en) 1994-12-13 1998-10-13 スミスクライン・ビーチャム・コーポレイション Bicyclic fibrinogen antagonist
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5578629A (en) 1995-03-29 1996-11-26 Merck & Co., Inc. Benzamide-containing inhibitors of farnesyl-protein transferase
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9507799D0 (en) 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
US5936089A (en) 1995-05-29 1999-08-10 Pfizer Inc Dipeptides which promote release of growth hormone
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU7139996A (en) 1995-10-05 1997-04-28 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
US6127427A (en) 1995-11-23 2000-10-03 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6066738A (en) 1996-01-30 2000-05-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507589A (en) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド Farnesyl-protein transferase inhibitor
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5965578A (en) 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5885995A (en) 1996-04-03 1999-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715603B2 (en) 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891337A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2251955A1 (en) 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
WO1997045412A1 (en) 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
EP0937073A2 (en) 1996-10-11 1999-08-25 Cor Therapeutics, Inc. Selective factor xa inhibitors
DE19647382A1 (en) 1996-11-15 1998-05-20 Hoechst Ag Heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists
IL129477A0 (en) 1996-11-22 2000-02-29 Elan Pharm Inc N-(aryl/heteroaryl)amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
IL129504A0 (en) 1996-11-22 2000-02-29 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl) amino acid amides pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
ATE295346T1 (en) 1996-11-22 2005-05-15 Elan Pharm Inc N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR INHIBITING BETA-AMYLOID RELEASE AND/OR SYNTHESIS THEREOF USING THESE COMPOUNDS
WO1998022441A2 (en) 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide and/or its synthesis
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
PL196641B1 (en) * 1996-12-23 2008-01-31 Elan Pharm Inc Cycloalkylic, lactamic, lactonic and affinite compounds, pharmaceutic agents containing them and methods of inhibiting ß-amyloid peptide release and/or synthesis thereof employing such compounds
CA2276081A1 (en) 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibitors of farnesyl-protein transferase
DK0968206T3 (en) 1997-02-19 2007-03-26 Berlex Inc N-heterocyclic derivatives as NOS inhibitors
WO1998041510A1 (en) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Novel benzolactam derivatives and medicinal compositions comprising the same
US5985900A (en) 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc A method of treating cancer
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
DE19726427A1 (en) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidine-2,4,6-trione derivatives, processes for their preparation and medicaments containing these compounds
GB9715030D0 (en) 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
NZ502876A (en) 1997-08-11 2001-11-30 Cor Therapeutics Inc Fused bicyclic lactam selective factor Xa inhibitors for treating thrombosis related diseases
NZ502803A (en) 1997-08-11 2001-11-30 Cor Therapeutics Inc Selective factor Xa inhibitors for treating diseases such as angina, myocardial infarction, transient ischemic attacks or diseases associated with undesired thrombosis
EP1027042A4 (en) 1997-09-29 2004-08-18 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
KR20010033408A (en) * 1997-12-22 2001-04-25 진 엠. 듀발 Polycyclic α-Amino-ε-Caprolactams and Related Compounds
IL137628A (en) 1998-02-20 2005-09-25 Deep Video Imaging Ltd Multi-layer display and a method for displaying images on such a display
PA8469501A1 (en) * 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
AU4710499A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
JP2002518481A (en) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2002518482A (en) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド Compounds that inhibit β-amyloid peptide release and / or its synthesis
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
CA2346099A1 (en) 1998-11-12 2000-05-18 Dupont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
BR9917082A (en) * 1998-12-24 2001-11-06 Du Pont Pharm Co Compounds that inhibit the production of "beta" proteins, a method of treating neurological disorders associated with the production of "beta" -amyloid, pharmaceutical composition and, method of inhibiting y-secretase activity
AU2001239791A1 (en) 2000-02-17 2001-08-27 Du Pont Pharmaceuticals Company Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production

Also Published As

Publication number Publication date
US6525044B2 (en) 2003-02-25
WO2001060826A3 (en) 2002-01-17
US20020055501A1 (en) 2002-05-09
CA2395862A1 (en) 2001-08-23
EP1261610A2 (en) 2002-12-04
JP2003523345A (en) 2003-08-05
WO2001060826A2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2001239791A1 (en) Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
AU2001257006A1 (en) Substituted lactams as inhibitors of abeta protein production
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU2002213485A1 (en) Inhibitors of protein kinases
AU2002256418A1 (en) Inhibitors of bace
AU7997700A (en) Amino lactam sulfonamides as inhibitors of abeta protein production
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU2002331311A1 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
AU2002324468A1 (en) Rapid improvement of cognition in conditions related to abeta
AU2002367147A1 (en) Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
AU2003211093A1 (en) Inhibitors of rgs proteins
AU2001216218A1 (en) Heterocyclic analgesic compounds and method of use thereof
AU2001275530A1 (en) Inhibitors of c-reactive protein induced inflammation
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2002247124A1 (en) Neurotherapeutic use of carboxypeptidase inhibitors
AU2001244692A1 (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
AU2002214286A1 (en) Method of profiling protein
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002238103A1 (en) Use of beta-lactamase inhibitors as neuroprotectants
AU1929301A (en) Methods of use of peptide deformylase inhibitors as novel antibacterial agents
AU2003295638A1 (en) NOVEL INHIBITORS OF Beta-LACTAMASE
AU2001249477A1 (en) Lactams as inhibitors of a-beta protein production
AU2002354363A1 (en) Method of activating protein
AU2002305868A1 (en) Inhibitors of reggamma